Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Down 51.8% in July

Innate Pharma SA (OTCMKTS:IPHYF) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 3,770 shares, a decrease of 51.8% from the July 15th total of 7,824 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Approximately 0.0% of the company’s stock are sold short.

Innate Pharma Stock Performance

IPHYF stock remained flat at $1.65 during mid-day trading on Friday. The business has a fifty day simple moving average of $1.65 and a 200 day simple moving average of $1.78. Innate Pharma has a 12-month low of $1.37 and a 12-month high of $2.25.

Innate Pharma Company Profile

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.